E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Diabetes Mellitus, Type 2 |
Diabetes Mellitus 2. typu |
|
E.1.1.1 | Medical condition in easily understood language |
Type 2 diabetes |
Diabetes 2. typu |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10045242 |
E.1.2 | Term | Type II diabetes mellitus |
E.1.2 | System Organ Class | 100000004861 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare the effect on glycaemic control of treatment with once weekly insulin 287 using two different switch approaches versus once daily insulin glargine U100 both in combination with metformin ± DPP4i ± SGLT2i in basal insulin analogue treated T2DM subjects |
|
E.2.2 | Secondary objectives of the trial |
To compare the safety and tolerability of once weekly insulin 287 using 2 different switch
approaches versus once daily insulin glargine U100 both in combination with metformin ± DPP4i
± SGLT2i in basal insulin analogue treated T2DM subjects |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Male or female, aged 18-75 years (both inclusive) at the time of signing informed consent.
2. Diagnosed with type 2 diabetes mellitus equal to or more than 180 days prior to the day of screening.
3. HbA1c of 7.0-10.0% (53.0-85.8 mmol/mol) (both inclusive) as assessed by central laboratory.
4. Treated with once daily or twice daily basal insulin analogue (insulin degludec, insulin detemir, insulin glargine U100 or U300, total daily dose of 10-50 U, both inclusive) equal to or more than 90 days prior to the day of screening.
5. Stable daily dose(s) for 90 days prior to the day of screening of any of the following antidiabetic drug(s) or combination regime(s):
a. Any metformin formulations equal to or above 1500 mg or maximum tolerated or effective dose (as documented in subject’s medical records)
b. Free or fixed combination therapy: Metformin as outlined above with or without DPP4i with or without SGLT2i is allowed:
b. 1: DPP4i (equal to or above half of the maximum approved dose according to local label or maximum tolerated or effective dose)
b.2: SGLT2i (equal to or above half of the maximum approved dose according to local label or maximum tolerated or effective dose )
6. Body mass index (BMI) equal to or below 40.0 kg/m^2 |
|
E.4 | Principal exclusion criteria |
1. Known or suspected hypersensitivity to trial product(s) or related products.
2. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method.
3. Participation in any clinical trial of an approved or non-approved investigational medicinal product within 90 days before screening.
4. Any disorder, except for conditions associated with type 2 diabetes mellitus, which in the investigator’s opinion might jeopardise subject’s safety or compliance with the protocol.
5. Any episodes of diabetic ketoacidosis within the past 90 days prior to the day of screening and between screening and randomisation.
6. Known hypoglycaemic unawareness as indicated by the Investigator according to Clarke’s questionnaire question 8.
7. Recurrent severe hypoglycaemic episodes within the last year as judged by the Investigator.
8. Myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient ischaemic attack within 180 days prior to the day of screening and between screening and randomisation. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Time in target range 3.9–10.0 mmol/L (70-180 mg/dL) measured using continuous glucose monitoring (CGM) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
During the last 2 weeks of treatment (week 15 and 16) |
|
E.5.2 | Secondary end point(s) |
1. Change in HbA1c
2. Change in fasting plasma glucose (FPG)
3. Change in body weight
4. Weekly insulin dose
5. Number of treatment emergent adverse events (TEAEs)
6. Number of severe hypoglycaemic episodes (level 3)
7. Number of clinically significant hypoglycaemic episodes (level 2) (below 3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3)
8. Number of hypoglycaemic alert episodes (level 1) (equal to or above 3.0 and below 3.9 mmol/L (equal to or above 54 and below 70 mg/dL), confirmed by BG meter) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1.-3. From baseline week 0 (V2) to week 16 (V18)
4. During the last 2 weeks of treatment (week 15 and 16)
5. From baseline week 0 (V2) to week 21 (V20)
6.-8. From baseline week 0 (V2) to week 16 (V18) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Tolerability |
Snášenlivost |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 16 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
European Union |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
Poslední studijní návštěva subjektu |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | 14 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 8 |
E.8.9.2 | In all countries concerned by the trial days | 14 |